Rubus coreanus (R. coreanus) possesses properties that may decrease cholesterol levels. The effects of unripe R. coreanus (uRC) consumption on low-density lipoprotein (LDL) and total cholesterol levels related to decreased circulating apolipoprotein (Apo) B and oxidized LDL levels were evaluated. This randomized, double-blind, placebo-controlled study included subjects with borderline-high cholesterol levels (between 200 and 239 mg/dL) who consumed one capsule daily containing 600 mg of freeze-dried uRC extract (n = 39) or the placebo (n = 38). After 12 weeks, the uRC group showed reductions of 21.23 ± 4.36 mg/dL in total cholesterol levels (P = 0.007) and 15.61 ± 4.16 mg/dL in LDL cholesterol levels (P = 0.032). In addition, significantly greater reductions in Apo B levels were observed in the uRC group (− 3.48 ± 3.40 mg/dL), but Apo B levels were increased in the placebo group (6.21 ± 2.84 mg/dL; P = 0.032). Furthermore, a remarkably lower oxidized LDL level was detected in the uRC group (57.76 ± 2.07 U/L) than in the placebo group (66.09 ± 3.47 U/L) after 12 weeks of consumption (P = 0.044). Because of its cholesterol-lowering effect, uRC shows great promise as a therapeutic agent for subjects with borderline-high total blood cholesterol levels. ClinicalTrials.gov Identifier: NCT03649620 (8/28/2018, retrospectively registered).

中文翻译：

---

未成熟悬钩子的降低胆固醇作用与胆固醇水平处于临界高水平的受试者中氧化 LDL 和载脂蛋白 B 水平的降低有关：一项随机对照试验。

悬钩子 (R. coreanus) 具有降低胆固醇水平的特性。评估了未成熟的 R. coreanus (uRC) 消耗对低密度脂蛋白 (LDL) 和总胆固醇水平的影响，这些水平与循环载脂蛋白 (Apo) B 和氧化 LDL 水平降低相关。这项随机、双盲、安慰剂对照研究纳入了胆固醇水平处于临界高水平（200 至 239 mg/dL 之间）的受试者，他们每天服用一粒含有 600 mg 冻干 uRC 提取物的胶囊（n = 39）或安慰剂（n = 38）。12 周后，uRC 组的总胆固醇水平降低了 21.23 ± 4.36 mg/dL (P = 0.007)，LDL 胆固醇水平降低了 15.61 ± 4.16 mg/dL (P = 0.032)。此外，uRC 组的 Apo B 水平显着降低（− 3.48 ± 3.40 mg/dL），但安慰剂组的 Apo B 水平有所增加（6.21 ± 2.84 mg/dL；P = 0.032）。此外，食用 12 周后，uRC 组的氧化 LDL 水平 (57.76 ± 2.07 U/L) 显着低于安慰剂组 (66.09 ± 3.47 U/L) (P = 0.044)。由于其降低胆固醇的作用，uRC 作为治疗血液总胆固醇水平处于临界高水平的受试者的治疗剂显示出巨大的前景。ClinicalTrials.gov 标识符：NCT03649620（2018 年 8 月 28 日，回顾性注册）。